Has a histologically or cytologically confirmed diagnosis of stage IV NSCLC;
Has not received prior systemic treatment for metastatic NSCLC;
Has measurable disease based on RECIST 1.1.
Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.
Has adequate organ function.
Has provided tumor tissue from locations not radiated prior to biopsy.
You may not be if
Previous immunotherapy (e.g. anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways)
Previously untreated or symptomatic central nervous system (CNS) metastases
Has received a live-virus vaccination within 28 days of planned treatment start.
Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody and chemotherapy.
Has or had active autoimmune disease.
Clareo Health | Study of KN046 With Chemotherapy in First Line Advanced NSCLC
